Pfizer Inc Stock Today

PFE Stock  USD 26.21  0.38  1.47%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 31

 
High
 
Low
Below Average
Pfizer is trading at 26.21 as of the 30th of November 2024, a 1.47 percent increase since the beginning of the trading day. The stock's lowest day price was 25.77. Pfizer has about a 31 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Note, on November 22, 2024, Representative Laurel Lee of US Congress acquired $15k to $50k worth of Pfizer Inc's common stock.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
13th of August 2012
Category
Healthcare
Classification
Health Care
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. The company has 5.67 B outstanding shares of which 94.54 M shares are at this time shorted by investors with about 2.07 days to cover. More on Pfizer Inc

Moving together with Pfizer Stock

  0.8HLN Haleon plcPairCorr
  0.85JNJ Johnson Johnson Sell-off TrendPairCorr
  0.76ANRO Alto Neuroscience,PairCorr
  0.72SHG Shinhan FinancialPairCorr

Moving against Pfizer Stock

  0.89FNMFO Federal National MortgagePairCorr
  0.71AXP American Express Fiscal Year End 24th of January 2025 PairCorr
  0.66TRV The Travelers Companies Fiscal Year End 17th of January 2025 PairCorr
  0.56AVAL Grupo AvalPairCorr
  0.53CIB Bancolombia SA ADRPairCorr
  0.4KB KB Financial GroupPairCorr

Pfizer Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Chairman CEOAlbert DVM
Thematic IdeaRobots And Drones (View all Themes)
Old Names[Pfizer Inc, Pfizer Inc, Pfizer Inc]
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, NYSE 100 Index, SP 500 Index, ARCA Institutional, ARCA Pharmaceutical, SP 100, BETTERINVESTING 100 INDEX, BTRINVSTNG 100 INDEX, SP 100 Index, Dow Jones Composite, Robots And Drones, Health Care, Pharmaceuticals, Drug Manufacturers—General, Healthcare (View all Sectors)
Excise Tax ActivitiesAnimal TestingCatholic
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Return On Assets0.00890.0094
Notably Down
Pretty Stable
Asset Turnover0.250.2583
Sufficiently Down
Slightly volatile
Gross Profit Margin0.620.4925
Significantly Up
Slightly volatile
Net Debt75.8 B72.2 B
Sufficiently Up
Slightly volatile
Total Current Liabilities50.2 B47.8 B
Sufficiently Up
Slightly volatile
Non Current Liabilities Total93.9 B89.4 B
Sufficiently Up
Slightly volatile
Total Assets237.8 B226.5 B
Sufficiently Up
Slightly volatile
Total Current Assets32.2 B43.3 B
Way Down
Very volatile
Total Cash From Operating Activities12.4 B8.7 B
Significantly Up
Pretty Stable
Debt Levels
Pfizer can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Pfizer's financial leverage. It provides some insight into what part of Pfizer's total assets is financed by creditors.
Liquidity
Pfizer Inc has 75.04 B in debt with debt to equity (D/E) ratio of 0.4, which is OK given its current industry classification. Pfizer Inc has a current ratio of 1.56, which is typical for the industry and considered as normal. Note however, debt could still be an excellent tool for Pfizer to invest in growth at high rates of return.

Change To Inventory

6.51 Billion
Pfizer Inc (PFE) is traded on New York Stock Exchange in USA. It is located in 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 and employs 88,000 people. Pfizer is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a total capitalization of 148.53 B. Pfizer Inc runs under Pharmaceuticals sector within Health Care industry. The entity has 5.67 B outstanding shares of which 94.54 M shares are at this time shorted by investors with about 2.07 days to cover. Pfizer Inc has about 2.85 B in cash with 8.7 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.44.
Check Pfizer Probability Of Bankruptcy
Ownership Allocation
Pfizer owns a total of 5.67 Billion outstanding shares. Over half of Pfizer's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that on November 22, 2024, Representative Laurel Lee of US Congress acquired $15k to $50k worth of Pfizer Inc's common stock.
Check Pfizer Ownership Details

Pfizer Stock Institutional Holders

InstituionRecorded OnShares
Capital World Investors2024-09-30
53.7 M
Bank Of America Corp2024-06-30
52.4 M
Amundi2024-06-30
50.2 M
Legal & General Group Plc2024-06-30
46.6 M
Bank Of New York Mellon Corp2024-06-30
41.9 M
Ubs Asset Mgmt Americas Inc2024-09-30
38.1 M
Jpmorgan Chase & Co2024-06-30
37.2 M
Goldman Sachs Group Inc2024-06-30
34.9 M
Dimensional Fund Advisors, Inc.2024-09-30
33.4 M
Vanguard Group Inc2024-09-30
516.2 M
Blackrock Inc2024-06-30
424.4 M
View Pfizer Diagnostics

Pfizer Historical Income Statement

At present, Pfizer's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Gross Profit is expected to grow to about 30.4 B, whereas Other Operating Expenses is forecasted to decline to about 28.8 B. View More Fundamentals

Pfizer Stock Against Markets

Pfizer Corporate Directors

Helen HobbsIndependent DirectorProfile
Shantanu NarayenLead Independent DirectorProfile
James SmithIndependent DirectorProfile
Susan DesmondHellmannIndependent DirectorProfile
When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.98)
Dividend Share
1.67
Earnings Share
0.75
Revenue Per Share
10.493
Quarterly Revenue Growth
0.312
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.